Polarean Imaging PLC
LSE:POLX
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Polarean Imaging PLC
LSE:POLX
|
965.6k GBP |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
190.8B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
173.9B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
139.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
116.7B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
106.2B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
45.6B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
48.5B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
36.8B USD |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Polarean Imaging PLC
Glance View
Polarean Imaging Plc.operates as a medical drug-device combination company serving the medical imaging market in the United States and internationally. The company is headquartered in Durham, North Carolina and currently employs 21 full-time employees. The company went IPO on 2018-03-29. The firm with its subsidiaries operates in the medical imaging market and develops equipment to enable existing magnetic resonance imaging (MRI) systems. The firm develops equipment that enables existing MRI systems to attain an improved level of pulmonary function imaging and specializes in the use of hyperpolarised Xenon gas (129Xe) as an imaging agent to visualize ventilation. 129Xe gas is being studied for visualization of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue barrier, and into the pulmonary bloodstream. 129Xe used to evaluate pulmonary function and to visualize the lung using MRI. The firm operates in an area of unmet medical need and its technology provides an investigational diagnostic approach, offering a non-invasive and radiation-free functional imaging platform.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Polarean Imaging PLC is 45.2%, which is above its 3-year median of 42.7%.
Over the last 3 years, Polarean Imaging PLC’s Gross Margin has increased from 36.1% to 45.2%. During this period, it reached a low of 33.7% on Dec 31, 2022 and a high of 46.1% on Dec 31, 2024.
